Free Trial

Arcus Biosciences (RCUS) News Today

Arcus Biosciences logo
$14.62 +0.11 (+0.76%)
(As of 11/20/2024 ET)
Arcus Biosciences, Inc. stock logo
GSA Capital Partners LLP Has $2.87 Million Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)
GSA Capital Partners LLP boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 17.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 187,415 shares of the company's stock after purchasing an additional 28,307 shares during
HC Wainwright Has Bearish Forecast for RCUS FY2024 Earnings
Arcus Biosciences (NYSE:RCUS) Given "Outperform" Rating at Wedbush
Arcus Biosciences, Inc. stock logo
Equities Analysts Offer Predictions for RCUS FY2024 Earnings
Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Investment analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Arcus Biosciences in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst E. Bodnar now forecasts that the c
Arcus Biosciences Reports Q3 2024 Results
Barclays Sticks to Its Buy Rating for Arcus Biosciences (RCUS)
Arcus Biosciences, Inc. stock logo
Arcus Biosciences (NYSE:RCUS) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS
Arcus Biosciences (NYSE:RCUS - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.07. The business had revenue of $48.00 million during the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative net margin of 100.81% and a negative return on equity of 42.86%. The company's quarterly revenue was up 50.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.94) EPS.
Arcus Biosciences, Inc. stock logo
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of "Buy" from Analysts
Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) has earned a consensus rating of "Buy" from the ten brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a
Arcus Biosciences, Inc. stock logo
Arcus Biosciences (NYSE:RCUS) Given Neutral Rating at HC Wainwright
HC Wainwright reiterated a "neutral" rating and issued a $20.00 target price on shares of Arcus Biosciences in a report on Wednesday.
Arcus Biosciences announces results from Part 1 of ARC-10 trial
Arcus Biosciences, Inc. stock logo
Arcus Biosciences (RCUS) Set to Announce Earnings on Wednesday
Arcus Biosciences (NYSE:RCUS) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638380)
Arcus Biosciences: Advancing On Several Fronts
Arcus Biosciences, Inc. stock logo
Arcus Biosciences (NYSE:RCUS) Trading Down 5.3% - Should You Sell?
Arcus Biosciences (NYSE:RCUS) Trading Down 5.3% - Here's Why
Arcus Biosciences price target raised to $29 from $25 at Barclays
Arcus Biosciences, Inc. stock logo
Arcus Biosciences (NYSE:RCUS) Sees Large Volume Increase - Should You Buy?
Arcus Biosciences (NYSE:RCUS) Sees Strong Trading Volume - What's Next?
Arcus Biosciences initiated with a Neutral at H.C. Wainwright
Arcus Biosciences, Inc. stock logo
What is HC Wainwright's Forecast for RCUS Q3 Earnings?
Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2024 earnings estimates for shares of Arcus Biosciences in a research report issued on Monday, October 21st. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($1.05)
Arcus Biosciences (RCUS) Gets a Buy from Truist Financial
Arcus Biosciences, Inc. stock logo
Arcus Biosciences (NYSE:RCUS) Shares Gap Down - Time to Sell?
Arcus Biosciences (NYSE:RCUS) Shares Gap Down - What's Next?
Arcus Biosciences, Inc. stock logo
Arcus Biosciences (NYSE:RCUS) Receives New Coverage from Analysts at HC Wainwright
HC Wainwright started coverage on shares of Arcus Biosciences in a research report on Monday. They set a "neutral" rating and a $20.00 price objective for the company.
Barclays Issues a Buy Rating on Arcus Biosciences (RCUS)
Arcus Biosciences, Inc. stock logo
SG Americas Securities LLC Trims Stake in Arcus Biosciences, Inc. (NYSE:RCUS)
SG Americas Securities LLC trimmed its stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 76.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,069 shares of the company's stock after selling
Arcus Biosciences, Inc. stock logo
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Buy" from Analysts
Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) has earned an average recommendation of "Buy" from the nine research firms that are covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation
Arcus Biosciences, Inc. stock logo
Arcus Biosciences (NYSE:RCUS) Stock Price Down 5.1% - Here's What Happened
Arcus Biosciences (NYSE:RCUS) Shares Down 5.1% - Here's Why
Get Arcus Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.

When it comes to NVDA… “acceleration cycles” are the key (Ad)

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

RCUS Media Mentions By Week

RCUS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RCUS
News Sentiment

-0.07

0.45

Average
Medical
News Sentiment

RCUS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RCUS Articles
This Week

2

5

RCUS Articles
Average Week

Get Arcus Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NYSE:RCUS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners